Effects of the Contraceptive Implant in Women With Sickle Cell Disease

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
University of Pennsylvania
Study ID
NCT05730205
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 45 Years
Healthy Volunteers
Not accepted

Interventions

  • Nexplanon 68 MG Drug Implant — DRUG
    Progestin contraceptive device

Study Details

The objective of this study is to measure the acceptability and impact of the progestin implant on frequency of vaso-occlusive crises, quality of life, and hematologic parameters in women with SCD.

Key Dates

Start date
Jun 8, 2023
Status verified
Jul 2025
Primary completion
Jun 15, 2026
Completion
Jun 15, 2026

Study Design

Enrollment
22 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Active Comparator: Nexplanon
  • No Intervention: Baseline

Primary Outcome Measure

Frequency of vaso-occlusive crises [ Time Frame: 9 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Penn Medicine University CityPhiladelphiaPennsylvania19104
Arden McAllister

Find similar trials in Philadelphia, PA

By condition
Sickle cell disease
By research site
Penn Medicine University City· Philadelphia, PA

Related Studies